Acer Therapeutics Inc
ACER
ACER was delisted on the 8th of November, 2023.
34 hedge funds and large institutions have $76.2M invested in Acer Therapeutics Inc in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 5 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 4
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
25% more capital invested
Capital invested by funds: $60.9M → $76.2M (+$15.3M)
21% more funds holding
Funds holding: 28 → 34 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.41M |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$1.23M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.18M |
| 4 |
Goldman Sachs
New York
|
+$625K |
| 5 |
Barclays
London,
United Kingdom
|
+$465K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$3.02M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$722K |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$448K |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$229K |
| 5 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$47.2K |
ACER Hedge Fund Activity: Q1 2019 in Review
34 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Acer Therapeutics Inc (ACER) for Q1 2019, worth a combined $76.2M — up 25% from $60.9M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ACER positions and 5 closed out — a net gain of 6 holders — while 10 added to existing stakes and 4 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $1.41M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $3.02M sold.
- 34 institutional investors held Acer Therapeutics Inc (ACER) as of Q1 2019, up from 28 in Q4 2018.
- Funds reported $76.2M of Acer Therapeutics Inc stock for Q1 2019, up 25% quarter-over-quarter.
- 11 funds opened new Acer Therapeutics Inc positions in Q1 2019 and 5 closed out, a net change of +6 holders.
- The largest Acer Therapeutics Inc buyer in Q1 2019 was Millennium Management, an estimated $1.41M added.
- The largest Acer Therapeutics Inc seller in Q1 2019 was Avoro Capital Advisors, an estimated $3.02M sold.
Based on aggregated 13F filings for Q1 2019.